0001179110-17-013874.txt : 20171108 0001179110-17-013874.hdr.sgml : 20171108 20171108162121 ACCESSION NUMBER: 0001179110-17-013874 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171106 FILED AS OF DATE: 20171108 DATE AS OF CHANGE: 20171108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Albers Jeffrey W. CENTRAL INDEX KEY: 0001638474 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 171186842 MAIL ADDRESS: STREET 1: BLUEPRINT MEDICINES CORP. STREET 2: 215 FIRST STREET, SUITE 340/350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 38 SIDNEY STREET, SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 38 SIDNEY STREET, SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2017-11-06 0 0001597264 Blueprint Medicines Corp BPMC 0001638474 Albers Jeffrey W. C/O BLUEPRINT MEDICINES CORPORATION 38 SIDNEY STREET, SUITE 200 CAMBRIDGE MA 02139 1 1 0 0 CEO and President Common Stock 2017-11-06 4 M 0 24514 1.87 A 30000 D Common Stock 2017-11-06 4 S 0 400 73.89 D 29600 D Common Stock 2017-11-06 4 S 0 1999 72.91 D 27601 D Common Stock 2017-11-06 4 S 0 2600 71.67 D 25001 D Common Stock 2017-11-06 4 S 0 7432 70.40 D 17569 D Common Stock 2017-11-06 4 S 0 16469 69.74 D 1100 D Common Stock 2017-11-06 4 S 0 1100 68.95 D 0 D Stock Option (Right to Buy) 1.87 2017-11-06 4 M 0 24514 0 D 2024-07-30 Common Stock 24514 825034 D The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.46 to $74.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.65 to $73.35 per share. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.23 to $72.13 per share. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.13 to $71.12 per share. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.13 to $70.12 per share. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.65 to $69.10 per share. This option was granted on July 30, 2014. This option vested as follows: (i) 12,620 shares vested in two installments at a rate of 6,310 shares on December 21, 2015 and May 21, 2016; (ii) 35,871 shares vested in three installments at a rate of 11,957 on June 21, 2016, July 21, 2016 and August 21, 2016; and (iii) 4,983 shares vested on September 21, 2016. /s/ Christopher Frankenfield, Attorney-in-Fact 2017-11-08